Cargando…

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial

PURPOSE: Erlotinib has been the only targeted agent to show significantly improved outcomes in pancreatic adenocarcinoma when combined with gemcitabine. We aimed to evaluate whether the addition of oxaliplatin to a combination gemcitabine/erlotinib treatment conferred a clinical benefit in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Sung Hee, Yun, Jina, Lee, Min-Young, Kim, Han Jo, Kim, Kyoung Ha, Kim, Se Hyung, Lee, Sang-Chul, Bae, Sang Byung, Kim, Chan Kyu, Lee, Namsu, Lee, Kyu Taek, Park, Seong Kyu, Lee, Yun Nah, Moon, Jong Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298866/ https://www.ncbi.nlm.nih.gov/pubmed/34296544 http://dx.doi.org/10.3349/ymj.2021.62.8.671

Ejemplares similares

Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

The incidence of venous thromboembolism is not lowin Korean patients with advanced pancreatic cancer
por: Yoon, Seug Yun, et al.
Publicado: (2018)

Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia
por: Kim, Hyun Jung, et al.
Publicado: (2012)

Safety and Effectiveness of Central Venous Catheterization in Patients with Cancer: Prospective Observational Study
por: Kim, Hyun Jung, et al.
Publicado: (2010)

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study
por: Kim, Jung Hoon, et al.
Publicado: (2018)

Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
por: Kwon, Ji Yeon, et al.
Publicado: (2011)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial
por: Patt, Yehuda Z., et al.
Publicado: (2017)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
por: Kim, Seung Tae, et al.
Publicado: (2016)

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2022)

Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial
por: Oh, In-Jae, et al.
Publicado: (2016)

Gyejigachulbu-Tang Relieves Oxaliplatin-Induced Neuropathic Cold and Mechanical Hypersensitivity in Rats via the Suppression of Spinal Glial Activation
por: Ahn, Byung-Soo, et al.
Publicado: (2014)

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
por: Ji, Young Sok, et al.
Publicado: (2016)

Prognostic impact of serum soluble PD-1 and ADV score for living donor liver transplantation in patients with previously untreated hepatocellular carcinoma
por: Hwang, Shin, et al.
Publicado: (2022)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy
por: Yun, Jina, et al.
Publicado: (2021)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
por: Park, Jin, et al.
Publicado: (2020)

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2019)

Association Between c-Met and Lymphangiogenic Factors in Patients With Colorectal Cancer
por: Kim, Han Jo, et al.
Publicado: (2018)

A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
por: Kim, Tae Hwan, et al.
Publicado: (2017)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
por: Baek, Sun Kyung, et al.
Publicado: (2019)

Epidemiologic study of Kawasaki disease in Korea, 1997-1999: comparison with previous studies during 1991-1996.
por: Park, Yong-Won, et al.
Publicado: (2002)

Long-term survival in a patient with acute promyelocytic leukemia with isolated meningeal relapse
por: Kim, Se Hyung, et al.
Publicado: (2010)

Association of the magnitude of the difference in blood pressure between office and ambulatory measurements with blood pressure variability in untreated individuals
por: Lee, Yea Je, et al.
Publicado: (2022)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
por: Chung, Kwang Hyun, et al.
Publicado: (2017)

GnRH Agonist Therapy in a Patient with Recurrent Ovarian Granulosa Cell Tumors
por: Kim, Hyun Jung, et al.
Publicado: (2009)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
por: Park, Seong Kyu, et al.
Publicado: (2011)

PM467. White-matter alterations related to duration of untreated periods in patients with recent-onset psychosis.
por: Lee, Sun-Woo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdc58iitaeb3bqh88b5mg6frd5